ACKNOWLEDGEMENTS
We thank CERCA Program / Generalitat de Catalunya for their
institutional support. We wish also to thank all the members of the ICO
Hereditary Cancer Program.
REFERENCES
Abou Tayoun, A. N., Pesaran, T., DiStefano, M. T., Oza, A., Rehm, H. L.,
Biesecker, L. G., . . . SVI), C. S. V. I. W. G. C. (2018).
Recommendations for interpreting the loss of function PVS1 ACMG/AMP
variant criterion. Hum Mutat, 39 (11), 1517-1524.
doi:10.1002/humu.23626
AlDubayan, S. H., Pyle, L. C., Gamulin, M., Kulis, T., Moore, N. D.,
Taylor-Weiner, A., . . . Lessel, D. (2019). Association of Inherited
Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility
to Testicular Germ Cell Tumors. JAMA Oncol .
doi:10.1001/jamaoncol.2018.6477
Balmaña, J., Digiovanni, L., Gaddam, P., Walsh, M. F., Joseph, V.,
Stadler, Z. K., . . . Domchek, S. M. (2016). Conflicting Interpretation
of Genetic Variants and Cancer Risk by Commercial Laboratories as
Assessed by the Prospective Registry of Multiplex Testing. J Clin
Oncol, 34 (34), 4071-4078. doi:10.1200/JCO.2016.68.4316
Bartek, J., Falck, J., & Lukas, J. (2001). CHK2 kinase–a busy
messenger. Nat Rev Mol Cell Biol, 2 (12), 877-886.
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C.,
Shannon, K. E., . . . Haber, D. A. (1999). Heterozygous germ line hCHK2
mutations in Li-Fraumeni syndrome. Science, 286 (5449), 2528-2531.
Bellosillo, B., Tusquets, I., Longarón, R., Pérez-Lezaun, A., Bellet,
M., Fabregat, X., . . . Solé, F. (2005). Absence of CHEK2 mutations in
Spanish families with hereditary breast cancer. Cancer Genet
Cytogenet, 161 (1), 93-95. doi:10.1016/j.cancergencyto.2005.01.016
ClinGen-TP53_Expert_Panel. (2019, August 6, 2020). TP53 Rule
Specifications for the ACMG/AMP
Variant Curation Guidelines. Retrieved fromhttps://www.clinicalgenome.org/affiliation/50013
Couch, F. J., Shimelis, H., Hu, C., Hart, S. N., Polley, E. C., Na, J.,
. . . Dolinsky, J. S. (2017). Associations Between Cancer Predisposition
Testing Panel Genes and Breast Cancer. JAMA Oncol, 3 (9),
1190-1196. doi:10.1001/jamaoncol.2017.0424
Cybulski, C., Gorski, B., Huzarski, T., Masojc, B., Mierzejewski, M.,
Debniak, T., . . . Lubinski, J. (2004). CHEK2 is a multiorgan cancer
susceptibility gene. Am J Hum Genet, 75 (6), 1131-1135.
Cybulski, C., Wokolorczyk, D., Huzarski, T., Byrski, T., Gronwald, J.,
Gorski, B., . . . Lubinski, J. (2007). A deletion in CHEK2 of 5,395 bp
predisposes to breast cancer in Poland. Breast Cancer Res Treat,
102 (1), 119-122.
Decker, B., Allen, J., Luccarini, C., Pooley, K. A., Shah, M., Bolla, M.
K., . . . Easton, D. F. (2017). Rare, protein-truncating variants in.J Med Genet, 54 (11), 732-741. doi:10.1136/jmedgenet-2017-104588
Easton, D. F., Pharoah, P. D. P., Antoniou, A. C., Tischkowitz, M.,
Tavtigian, S. V., Nathanson, K. L., . . . Foulkes, W. D. (2015).
Gene-panel sequencing and the prediction of breast-cancer risk.The New England journal of medicine, 372 (23), 2243-2257.
doi:10.1056/NEJMsr1501341
Fachal, L., Santamariña, M., Blanco, A., Carracedo, A., & Vega, A.
(2013). CHEK2 c.1100delC mutation among non-BRCA1/2 Spanish hereditary
breast cancer families. Clin Transl Oncol, 15 (2), 164-165.
doi:10.1007/s12094-012-0967-z
Feliubadaló, L., Tonda, R., Gausachs, M., Trotta, J. R., Castellanos,
E., López-Doriga, A., . . . Lázaro, C. (2017). Benchmarking of Whole
Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of
Hereditary Cancer. Sci Rep, 7 , 37984. doi:10.1038/srep37984
Fostira, F., Kostantopoulou, I., Apostolou, P., Papamentzelopoulou, M.
S., Papadimitriou, C., Faliakou, E., . . . Yannoukakos, D. (2020). One
in three highly selected Greek patients with breast cancer carries a
loss-of-function variant in a cancer susceptibility gene. J Med
Genet, 57 (1), 53-61. doi:10.1136/jmedgenet-2019-106189
Gutiérrez-Enríquez, S., Balmaña, J., Baiget, M., & Díez, O. (2008).
Detection of the CHEK2 1100delC mutation by MLPA BRCA1/2 analysis: a
worthwhile strategy for its clinical applicability in 1100delC
low-frequency populations? Breast Cancer Res Treat, 107 (3),
455-457. doi:10.1007/s10549-007-9555-2
Han, F. F., Guo, C. L., & Liu, L. H. (2013). The effect of CHEK2
variant I157T on cancer susceptibility: evidence from a meta-analysis.DNA Cell Biol, 32 (6), 329-335. doi:10.1089/dna.2013.1970
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi,
J., Wang, Q., . . . MacArthur, D. G. (2019). Variation across 141,456
human exomes and genomes reveals the spectrum of loss-of-function
intolerance across human protein-coding genes. bioRxiv , 531210.
doi:10.1101/531210
Katona, B. W., Yurgelun, M. B., Garber, J. E., Offit, K., Domchek, S.
M., Robson, M. E., & Stadler, Z. K. (2018). A counseling framework for
moderate-penetrance colorectal cancer susceptibility genes. Genet
Med, 20 (11), 1324-1327. doi:10.1038/gim.2018.12
Kopanos, C., Tsiolkas, V., Kouris, A., Chapple, C. E., Albarca Aguilera,
M., Meyer, R., & Massouras, A. (2018). VarSome: the human genomic
variant search engine. Bioinformatics, 35 (11), 1978-1980.
doi:10.1093/bioinformatics/bty897
Kraus, C., Hoyer, J., Vasileiou, G., Wunderle, M., Lux, M. P., Fasching,
P. A., . . . Reis, A. (2017). Gene panel sequencing in familial
breast/ovarian cancer patients identifies multiple novel mutations also
in genes others than BRCA1/2. Int J Cancer, 140 (1), 95-102.
doi:10.1002/ijc.30428
Liang, M., Zhang, Y., Sun, C., Rizeq, F. K., Min, M., Shi, T., & Sun,
Y. (2018). Association Between CHEK2*1100delC and Breast Cancer: A
Systematic Review and Meta-Analysis. Mol Diagn Ther .
doi:10.1007/s40291-018-0344-x
M Kriege, A. H., A Jager, P E A Huijts, E M Berns, A M Sieuwerts, M E
Meijer-van Gelder,, & J M Collée, P. D., M J Hooning, J W M Martens and
C Seynaeve. (2014). Survival and contralateral breast cancer in
CHEK2 1100delC breast cancer patients:
impact of adjuvant chemotherapy. British Journal of Cancer, 111 ,
1004–1013. doi:10.1038/bjc.2014.306
Martínez-Bouzas, C., Beristain, E., Guerra, I., Gorostiaga, J.,
Mendizabal, J. L., De-Pablo, J. L., . . . Tejada, M. I. (2007). CHEK2
1100delC is present in familial breast cancer cases of the Basque
Country. Breast Cancer Res Treat, 103 (1), 111-113.
doi:10.1007/s10549-006-9351-4
Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K., & Elledge,
S. J. (2000). Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo
and in vitro. Proc Natl Acad Sci U S A, 97 (19), 10389-10394.
Meijers-Heijboer, H., van den Ouweland, A., Klijn, J., Wasielewski, M.,
de Snoo, A., Oldenburg, R., . . . Stratton, M. R. (2002). Low-penetrance
susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers
of BRCA1 or BRCA2 mutations. Nat Genet, 31 (1), 55-59.
Meijers-Heijboer, H., Wijnen, J., Vasen, H., Wasielewski, M., Wagner,
A., Hollestelle, A., . . . Schutte, M. (2003). The CHEK2 1100delC
mutation identifies families with a hereditary breast and colorectal
cancer phenotype. Am J Hum Genet, 72 (5), 1308-1314.
Oldenburg, R. A., Kroeze-Jansema, K., Kraan, J., Morreau, H., Klijn, J.
G., Hoogerbrugge, N., . . . Devilee, P. (2003). The CHEK2*1100delC
variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2
multiple-case families. Cancer Res, 63 (23), 8153-8157.
Plon, S. E., Cooper, H. P., Parks, B., Dhar, S. U., Kelly, P. A.,
Weinberg, A. D., . . . Hilsenbeck, S. (2008). Genetic testing and cancer
risk management recommendations by physicians for at-risk relatives.Genet Med, 13 (2), 148-154.
Richards, C. S., Bale, S., Bellissimo, D. B., Das, S., Grody, W. W.,
Hegde, M. R., . . . Ward, B. E. (2008). ACMG recommendations for
standards for interpretation and reporting of sequence variations:
Revisions 2007. Genetics in medicine : official journal of the
American College of Medical Genetics, 10 (4), 294-300.
doi:10.1097/GIM.0b013e31816b5cae
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J.,
. . . Rehm, H. L. (2015). Standards and guidelines for the
interpretation of sequence variants: a joint consensus recommendation of
the American College of Medical Genetics and Genomics and the
Association for Molecular Pathology. Genet Med, 17 (5), 405-424.
doi:10.1038/gim.2015.30
Schmidt, M. K., Hogervorst, F., van Hien, R., Cornelissen, S., Broeks,
A., Adank, M. A., . . . Easton, D. F. (2016). Age- and Tumor
Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC
Carriers. J Clin Oncol, 34 (23), 2750-2760.
doi:10.1200/JCO.2016.66.5844
Senol-Cosar, O., Schmidt, R. J., Qian, E., Hoskinson, D., Mason-Suares,
H., Funke, B., & Lebo, M. S. (2019). Considerations for clinical
curation, classification, and reporting of low-penetrance and low effect
size variants associated with disease risk. Genet Med, 21 (12),
2765-2773. doi:10.1038/s41436-019-0560-8
Spurdle, A. B., Healey, S., Devereau, A., Hogervorst, F. B. L.,
Monteiro, A. N. A., Nathanson, K. L., . . . Enigma. (2012).
ENIGMA–evidence-based network for the interpretation of germline
mutant alleles: an international initiative to evaluate risk and
clinical significance associated with sequence variation in BRCA1 and
BRCA2 genes. Human mutation, 33 (1), 2-7. doi:10.1002/humu.21628
Stradella, A., Del Valle, J., Rofes, P., Feliubadaló, L., Grau Garces,
È., Velasco, À., . . . Lázaro, C. (2018). Does multilocus inherited
neoplasia alleles syndrome have severe clinical expression? J Med
Genet . doi:10.1136/jmedgenet-2018-105700
Szymanska-Pasternak, J., Szymanska, A., Medrek, K., Imyanitov, E. N.,
Cybulski, C., Gorski, B., . . . Lubinski, J. (2006). CHEK2 variants
predispose to benign, borderline and low-grade invasive ovarian tumors.Gynecol Oncol, 102 (3), 429-431. doi:10.1016/j.ygyno.2006.05.040
Tavtigian, S. V., Greenblatt, M. S., Harrison, S. M., Nussbaum, R. L.,
Prabhu, S. A., Boucher, K. M., . . . SVI), C. S. V. I. W. G. C. (2018).
Modeling the ACMG/AMP variant classification guidelines as a Bayesian
classification framework. Genet Med, 20 (9), 1054-1060.
doi:10.1038/gim.2017.210
Taylor, A., Brady, A. F., Frayling, I. M., Hanson, H., Tischkowitz, M.,
Turnbull, C., . . . (UK-CGG), U. C. G. G. (2018). Consensus for genes to
be included on cancer panel tests offered by UK genetics services:
guidelines of the UK Cancer Genetics Group. J Med Genet, 55 (6),
372-377. doi:10.1136/jmedgenet-2017-105188
Wu, X., Webster, S. R., & Chen, J. (2001). Characterization of
tumor-associated Chk2 mutations. J Biol Chem, 276 (4), 2971-2974.
Zannini, L., Delia, D., & Buscemi, G. (2014). CHK2 kinase in the DNA
damage response and beyond. J Mol Cell Biol, 6 (6), 442-457.
doi:10.1093/jmcb/mju045